Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 21,478 matching trials from the live ClinicalTrials.gov search.
Filters: Boston, Massachusetts Clear all
Terminated Phase 1 Interventional

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

NCT04336982
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
CC-90009, Venetoclax, Azacitidine, Gilteritinib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Nov 6, 2026, 5:28 AM EST
Completed Phase 4 Interventional Results available

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

NCT00442962
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Nov 6, 2026, 5:28 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Metabolomic Profiling of Novel Mediators of Vascular Function

NCT00762242
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
blood sampling and brachial artery ultrasound
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Nov 6, 2026, 5:28 AM EST
Active, not recruiting Phase 3 Interventional

Adjuvant Avelumab in Merkel Cell Cancer

NCT03271372
View directory record Official record
Conditions
Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
Interventions
Avelumab, Peripheral Blood Collection, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
9
States / cities
Orange, California • Aurora, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 6, 2026, 5:28 AM EST
Completed No phase listed Observational

A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

NCT05444972
View directory record Official record
Conditions
Myelofibrosis
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • West Hills, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Nov 6, 2026, 5:28 AM EST
Completed Phase 1 Interventional

Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease

NCT02989701
View directory record Official record
Conditions
Sickle Cell Disease Without Crisis
Interventions
Plerixafor
Drug
Lead sponsor
Alessandra Biffi
Other
Eligibility
18 Years to 35 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Nov 6, 2026, 5:28 AM EST
Completed Not applicable Interventional

Attention Training for Learning Enhancement and Resilience Trial

NCT02416401
View directory record Official record
Conditions
Age-related Cognitive Decline
Interventions
Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
65 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Nov 6, 2026, 5:28 AM EST
Terminated Phase 3 Interventional Results available

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

NCT01794000
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Prasugrel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Nov 6, 2026, 5:28 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02813265
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
918 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
60
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Nov 6, 2026, 5:28 AM EST
Completed Phase 2 Interventional Results available

Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention

NCT01188967
View directory record Official record
Conditions
Nicotine Dependence
Interventions
GSK598809, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Nov 6, 2026, 5:28 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Identification of Genetic Causes of Calcific Aortic Valve Disease

NCT04149600
View directory record Official record
Conditions
Calcific Aortic Stenosis, Calcific Aortic Stenosis - Bicuspid Valve, Aortic Valve Disease, Aortic Valve Calcification, Aortic Diseases, Aortic Aneurysm, Aortic Valve Cusp Abnormality, Aortic Valve Disease Mixed, Aortic Valve Insufficiency
Interventions
Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 6, 2026, 5:28 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

NCT01767311
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 6, 2026, 5:28 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

NCT02290834
View directory record Official record
Conditions
Impaired Cognition, Chemo-brain, Breast Cancer
Interventions
Cognitive, functional and subjective assessments, MRI, PET Scan
Other · Device · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 6, 2026, 5:28 AM EST
Completed Not applicable Interventional

Precision Clinical and Genetic Tools for Brain Health in Hemorrhagic Stroke

NCT05643001
View directory record Official record
Conditions
Hemorrhagic Stroke
Interventions
In-patient and out-patient electronic health record alert
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Nov 6, 2026, 5:28 AM EST
Not listed Phase 3 Interventional

EASE Trial: Exhale Airway Stents for Emphysema

NCT00391612
View directory record Official record
Conditions
Emphysema
Interventions
Exhale® Drug-Eluting Stent, Sham control
Device
Lead sponsor
Broncus Technologies
Industry
Eligibility
35 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Nov 6, 2026, 5:28 AM EST
Completed Phase 2 Interventional Results available

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

NCT01039519
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
Ganetespib
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Nov 6, 2026, 5:28 AM EST
Active, not recruiting Phase 2 Interventional Results available

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

NCT03085719
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 6, 2026, 5:28 AM EST
Completed Not applicable Interventional

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

NCT03500328
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 6, 2026, 5:28 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

NCT04437511
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
185
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 146 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 6, 2026, 5:28 AM EST
Recruiting Phase 3 Interventional

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

NCT06881992
View directory record Official record
Conditions
Tumor Hyperinsulinism (Tumor HI)
Interventions
Ersodetug
Drug
Lead sponsor
Rezolute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Bethesda, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 6, 2026, 5:28 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Improving Brain Development in Medically Healthy Premature Infants

NCT00065364
View directory record Official record
Conditions
Premature Birth
Interventions
Newborn Individualized Developmental Care Assessment Program
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
28 Weeks to 33 Weeks
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 6, 2026, 5:28 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis

NCT06461299
View directory record Official record
Conditions
Perioral Dermatitis
Interventions
Seysara Oral Product
Drug
Lead sponsor
The Dermatology Institute of Boston
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Nov 6, 2026, 5:28 AM EST
Completed Not applicable Interventional Results available

Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma

NCT00976898
View directory record Official record
Conditions
Liver Cancer
Interventions
Proton Beam Irradiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Nov 6, 2026, 5:28 AM EST
Completed Phase 1Phase 2 Interventional Results available

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

NCT03693612
View directory record Official record
Conditions
Neoplasms
Interventions
feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Nov 6, 2026, 5:28 AM EST